Sei Investments Co. Acquires 1,122 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

Sei Investments Co. lifted its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 4.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,198 shares of the biopharmaceutical company’s stock after buying an additional 1,122 shares during the quarter. Sei Investments Co. owned about 0.10% of Madrigal Pharmaceuticals worth $12,667,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Flagship Harbor Advisors LLC purchased a new position in Madrigal Pharmaceuticals in the 4th quarter valued at approximately $29,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth $39,000. Quarry LP bought a new position in shares of Madrigal Pharmaceuticals in the third quarter worth $39,000. Accent Capital Management LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 64.9% in the fourth quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 37 shares during the period. Finally, Johnson Financial Group Inc. purchased a new position in shares of Madrigal Pharmaceuticals in the third quarter valued at $50,000. 98.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MDGL has been the topic of a number of analyst reports. Truist Financial boosted their price objective on Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Citigroup restated an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. Evercore set a $649.00 target price on Madrigal Pharmaceuticals in a report on Thursday, May 7th. Canaccord Genuity Group upped their price target on Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. Fourteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $688.20.

Madrigal Pharmaceuticals Trading Down 5.2%

Shares of MDGL stock opened at $467.32 on Friday. The company has a market capitalization of $10.78 billion, a PE ratio of -36.25 and a beta of -1.05. Madrigal Pharmaceuticals, Inc. has a 52-week low of $290.00 and a 52-week high of $615.00. The business’s fifty day moving average is $516.48 and its 200 day moving average is $499.05. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.16 and a current ratio of 3.50.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative return on equity of 55.04% and a negative net margin of 25.32%.The business had revenue of $364.25 million for the quarter, compared to analyst estimates of $352.13 million. During the same period in the prior year, the company earned ($1.90) EPS. The company’s quarterly revenue was up 71.2% compared to the same quarter last year. On average, equities research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.45 EPS for the current fiscal year.

Insider Activity at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, Director Richard S. Levy sold 5,682 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total value of $2,928,730.08. Following the completion of the transaction, the director owned 22,015 shares of the company’s stock, valued at $11,347,411.60. The trade was a 20.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $495.74, for a total transaction of $516,561.08. Following the sale, the insider owned 10,033 shares in the company, valued at approximately $4,973,759.42. This trade represents a 9.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 7,568 shares of company stock worth $3,880,711. 17.60% of the stock is owned by company insiders.

Key Stories Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra continues to drive strong revenue growth. Second-quarter revenue reached $364.25 million, up 71.2% year over year and above the $352.13 million analyst consensus, reflecting continued demand for the company’s MASH drug. Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
• Positive Sentiment: The quarterly loss was narrower than expected. Madrigal reported a loss of $1.99 per share, beating estimates ranging from $2.55 to $2.68 per share, although the loss was wider than the $1.90-per-share loss recorded a year earlier. Madrigal Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support remains favorable. Wells Fargo assigned Madrigal an Overweight rating, providing a positive signal for the company’s outlook. Madrigal Earns Overweight Rating from Wells Fargo
• Neutral Sentiment: Madrigal’s earnings call and quarterly presentation highlighted Rezdiffra’s contribution to the business and the company’s ongoing development efforts, but investors are weighing the pace of the commercial launch against the stock’s elevated valuation. Madrigal Q2 2026 Earnings Call Transcript
• Negative Sentiment: Shares fell despite the earnings beat. Investors appear concerned that Rezdiffra’s commercial growth is moderating, making the strong year-over-year revenue increase less compelling and raising expectations for evidence of sustained prescribing and sales momentum. MDGL Stock Down Despite Q2 Beat

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.